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INTRODUCTION 
Ischemic heart disease (IHD) is a leading cause of death in the western 
world  and increased incidence  in our country also. Most of the subjects  with IHD 
have one or more traditional risk factors including diabetes, smoking history, 
hypertension, obesity, a family history of IHD and  hyperlipidimia.  In recent years 
new risk factors for IHD have been identified, including the presence of  
inflammation as demonstrated by raised highly sensitive C-reactive 
arthritis(RA),Antiphospholipid antibody syndrome and systemic lupus   
erthematosus also have  a greatly increased risk of developing IHD. 
The autoantibody rheumatoid factor (RF) is strongly  associated with  RA, 
may be  present in subjects many years  before they develop RA and its presence 
confers a risk of developing RA that increases with increasing titre. However  RF 
is associated  with other  autoimmune  rheumatic disease, viral  or bacterial 
infections and  is present  in as many as 15% of normal adults. Recently, RF has 
been associated with an increased likelihood of developing IHD in patients with 
inflammatory  polyarthrities. 
Presence of  RF in general population may identify the subjects with a 
similar immune pathology to patients  with RA ,who may also share an increased 
 
 
likelihood of developing IHD and that RF may have special role in  the 
pathogenisis of IHD. 
To explore this, the study was  conducted  whether  the presence of  RF was  
associated  with  increased risk of  IHD  among  general population.  
                
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To analyse the   RF is an indipendent  and additional risk factor  for IHD in 
general population. 
2. And comparing  in male/female ,and correlation between high titre and low 
titre  of  RF in the effect of IHD with or without traditional risk factor.                                
 
 
 
 
 
 
 
 
 
 
 
                   
                                        
 
 
REVIEW OF LITERATURE 
  The coronary  circulation  is  unique  in that it iresponsible  for generating 
the arterial pressure that is required to perfuse the systemic circulation and yet at 
the same time has its own  perfusion impeded during the systolic portion  of the 
cardiac cycle. Because myocardial contraction  is closely connected to coronary 
flow and oxygen  delivery,  the balance between oxygen supply and demand is a 
critical determinant of the normal beat to beat function  of the heart. When this 
relationship is acutely disturbed by disease affecting coronary blood flow, the 
resulting  imbalance can immediately precipitate a vicious cycle, where by 
ischemia-induced contractile dysfunction  precipitates hypotension  and further  
myocardial ischemia. IHD causes more deaths and disability and incurs greater 
economic costs than any other illness in the developed world. IHD is the most 
common, serious, chronic, life-threatening illness in the world wide.  A high fat 
and energy-rich diet, smoking, and a sedentary lifestyle are associated with the 
emergence of IHD.  In the United States and Western Europe, it is growing among 
low-income groups rather than high-income groups (who are adopting more 
healthful lifestyles), while primary prevention has delayed the disease to later in 
life in all socioeconomic groups. 
 
 
Obesity, insulin resistance, and type 2 diabetes mellitus are increasing and 
are powerful risk factors for IHD. With urbanization in the developing world, the 
prevalence of risk factors for IHD is increasing rapidly in these regions such that a 
majority of the global burden of IHD is now occurring in low-income and middle-
income countries. Population subgroups that appear to be particularly affected are 
men in South Asian countries, especially India. Given the projection of large 
increases in IHD throughout the world, IHD is likely to become the most common 
cause of death worldwide by 2020 
Central to an understanding of the pathophysiology of myocardial ischemia 
is the concept of myocardial supply and demand. Under normal conditions, for any 
given level of a demand for oxygen, the myocardium will be supplied with 
oxygen-rich blood to prevent underperfusion of myocytes and the subsequent 
development of ischemia and infarction.  
The major determinants of myocardial oxygen demand are heart rate, 
myocardial contractility,  and  myocardial wall tension (stress).  An adequate  
supply of  oxygen to the  myocardium  requires  a satisfactory  level of  oxygen-
carrying  capacity of  the  blood (determined by the inspired level of oxygen, 
pulmonary function, and hemoglobin concentration and function)  and an adequate 
level of coronary blood flow. Blood flows through the coronary arteries in a phasic 
 
 
fashion, with the majority occurring during diastole. About 75% of the total 
coronary resistance to flow occurs across three sets of arteries: 
    (1) large epicardial arteries  
(2) prearteriolar vessels  
           (3) arteriolar and intramyocardial capillary vessels.  
In the absence of significant flow-limiting atherosclerotic Obstruction, the 
normal  coronary  circulation  is dominated  and controlled by the heart's 
requirements of oxygen. This need is met by the ability of the coronary vascular 
bed to vary its resistance (and, therefore, blood flow) considerably while the 
myocardium extracts a high and relatively fixed percentage of oxygen. Normally, 
intramyocardial resistance vessels demonstrate an immense capacity for dilation. 
For example, the changing oxygen needs of the heart with exercise and emotional 
stress affect coronary vascular resistance and in this manner regulate the supply of 
oxygen and substrate to the myocardium (metabolic regulation). The coronary 
resistance vessels also adapt to physiologic alterations in blood pressure in order to 
maintain coronary blood flow at levels appropriate to myocardial needs 
(autoregulation). 
 
 
By reducing the lumen of the coronary arteries, atherosclerosis limits 
appropriate increases in perfusion when the demand for flow is augmented, as 
occurs during exertion or excitement. When the luminal reduction is severe, 
myocardial perfusion in the basal state is reduced. Coronary blood flow can also be 
limited by spasm, arterial thrombi, and, rarely, coronary emboli as well as by ostial 
narrowing due to aortitis. Congenital abnormalities,such as origin of the left 
anterior descending coronary artery from the pulmonary artery, may cause 
myocardial ischemia and infarction in infancy, but this cause is very rare in adults. 
Myocardial ischemia can also occur if myocardial oxygen demands are 
markedly increased and when coronary blood flow may be limited, as occurs in 
severe left ventricular hypertrophy due to aortic stenosis. The latter can present 
with angina that is indistinguishable from that caused by coronary atherosclerosis 
largely owing to subendocardial ischemia.A reduction in the oxygen-carrying 
capacity of the blood, as in extremely severe anemia or in the presence of 
carboxyhemoglobin, rarely causes myocardial  ischemia by itself but may lower 
the threshold for ischemia in patients with  moderate coronary obstruction. 
Not infrequently, two or more causes of ischemia coexist, such as an 
increase in oxygen demand due to LV hypertrophy secondary to  hypertension and 
a reduction in oxygen supply secondary to coronary atherosclerosis and anemia. 
Abnormal constriction or failure of normal dilation of the coronary resistance 
 
 
vessels can also cause ischemia. When it causes angina, this condition is referred to 
as microvascular angina. 
From a practical viewpoint, the cardiovascular risk factors that have 
emerged from such studies fall into two categories: those modifiable by lifestyle 
and/or pharmacotherapy and those that are essentially  unmodifiable. The weight 
of evidence supporting various risk factors differs. For example, 
hypercholesterolemia and hypertension certainly predict coronary risk, but other 
so-called nontraditional risk factors, such as levels of homocysteine, lipoprotein (a) 
, or infection, remain controversial. One must further distinguish factors that 
actually participate in atherogenesis from those that may merely serve as markers 
of risk without direct involvement in pathogenesis. The following Lists the risk 
factors recognized by the current National Cholesterol Education Project  Adult 
Treatment Panel- III. The sections below will consider some of  these risk factors 
and approaches to their modification. 
 
 Cigarette smoking  
 Hypertension (BP ≥ 140/90 mmHg or on antihypertensive 
medication) 
 Low HDL cholesterol[<1.0 mmol/L (<40 mg/dL)]  
 Diabetes mellitus 
 
 
 Family history of premature CHD 
o CHD in male first-degree relative <55 years  
o CHD in female first-degree relative <65 years  
• Age (men ≥45 years; women ≥55 years 
• Lifestyle risk factors  
o Obesity   
o Physical inactivity  
o Atherogenic diet  
• Emerging risk factors  
o Lipoprotein(a)  
o Homocysteine  
o Prothrombotic factors 
o Proinflammatory factors  
o Impaired fasting glucose  
o Subclinical atherogenesis 
Ischemic heart disease is most often due to atherosclerotic  coronary  artery  
disease. The importance  of  inflammation  in atherosclerosis  is  also  supported  
by  the  finding of   inflammatory  cells  in atherosclerotic  lesions . The  following  
conditions  are  associated  with inflammatory/ proinlammatory  factors  causative 
factors for IHD. 
 
 
                                 1) Rheumatoid arthritis 
                                  2) Systemic lupus erthymatosus 
                                   3) Antiphospholipid  antibody syndrome 
                                    4) Vassculitis producing other connective tissue disorders 
Of these inflammatory/ proinflammatory factor,  RF  is  one of the  
independent and additional risk factor for IHD.   
ROLE OF RHEUMATOID FACTOR  IN  IHD 
The association  of  RF with IHD  provides further  of  an  importance of 
inflammation and raises the possibility that  autoimmune  mechanisms may playing  
a part.   The  study  cannot determine  whether  RF   is a  non-specific marker of 
inflammation or is involved  directly  in   pathogenesis   of atherosclerosis in the 
subjects included.   However , RF appears  to cause direct tissue damage  in  RA  
as a constituent of immune  complexes, perhaps by activating complement. It 
might  cause  damage  to  the  vascular  endothelium  in the same  way.  
There  is circumstancial  evidence for this: Atherosclerotic  plaques  contain  
immunoglobulins and complements suggesting immune complex  activity. In 
addition  the  lack of    relationship  between  IHD and  the  autoantibodies  ANA  
and ACA  suggests  that  the association  between RF  and  IHD.This may not be   
due to  non-specific polyclonal  B-cell activation secondary to inflammation but 
the unique role of  RF in  the  pathogenesis  of atherosclerosis/IHD.  
 
 
This is further  supported  by  the association of  RF  with  IHD  in  subjects   
with  inflammatory arthritis. There  is  also  an  intriguing  possibility that  the  the  
pathological  process  involved  in  IHD  such as  atheroma  formation,  may  
generate  inflammatory  tissue capable of producing  RF.  Infections  cause  
inflammation  and  can  induce  RF  production, although  this is  usually  short  
lived. Chronic infections  that  induce  persistent RF  is  rare. Acute  infections  are 
associated  with  an increased  risk  of  cardiovascular  events, perhaps  by 
inducing  circulating  cytokines  or an  autoimmune  response.  
RHEUMATOID ARTHRITIS  (RA) 
Patients with rheumatoid arthritis have  an  increased prevalence  of  IHD. 
This is most likely in those  people  with  the  autoantibody RF.Which are strongly   
associated   with  RA  but is also  present in up to 15% of all adults.  
Atherosclerotic plaque is a complex inflammatory lesion characterized by  an   
infiltrate of macrophages and T cells. Intra plaque immune cells are activated and   
involved in mediating tissue injury. T-cell cytokines can drive macrophage 
activation in atherosclerotic lesions and can also regulate the acute-phase response. 
Indeed, T cells in patients with acute coronary syndromes (ACS) are 
skewedtoward  the production of interferon (IFN)-γ, a potent  monoyte activator 
largely derived  from a distinct subset of CD4+ T cells  that, in contrast to classic 
CD4+ helper T cells, lacks the  co-stimulatory molecule CD28. CD4+CD28null T 
 
 
cells are clonally expanded in ACS and invade the unstable  atherosclerotic  
plaque.                                
Moreover, CD4+CD28null T cells have cytotoxic  capability, can effectively 
kill  Endothelial cells in vitro, and  may contribute to endothelial cell injury in 
coronary plaque. Expansion of CD4+CD28null T cells was initially described in 
patients  with  rheumatoid arthritis (RA), a chronic autoimmune  disease of 
unknown etiology.  RA is characterized by chronic inflammation and hyperplasia 
of synovial tissue.  More  importantly, it is a quintessential systemic disease that 
can manifest in most major organ systems.                                               
T cells play a central  role in the Immune pathogenesis of RA and are the 
key regulators of the chronic destructive joint lesions. In addition, patients with RA 
have abnormalities in T-cell homeostasis that  affect the entire pool of T cells. One 
of the consequences of dysregulated T-cell homeostasis is the emergence  of large  
clonal CD4+CD28  null T-cell populations that are auto reactive  and cytotoxic, 
and infiltrate synovial tissue. The highest frequency of CD4+CD28null T cells is 
found in severe RA,  particularly in  patients with rheumatoid vasculitis.   
When the inflammatory   process in   RA spreads to extra-articular sites,   
such as mid-size  arteries  and capillaries,  morbidity  and mortality are clearly 
increased. The inflammatory mechanisms in RA may enhance atherogenesis  in 
several ways. C-reactive protein, a useful marker of disease  activity, is elevated in 
 
 
RA and has prognostic value.  It may also participate directly in endothelial injury 
by sensitizing endothelial cells to T-cell mediated cytotoxicity.                                                 
Circulating   cytokines in RA, such as TNF-α, result in endothelial  
activation and up-regulation of adhesion molecules. Indeed, endothelial 
dysfunction is frequently present in RA patients, even in the absence of identifiable 
Cardiovascular risk factors  and  improves with anti-TNF-α therapy . Cytokines 
will  also non-specifically activate monocytes and other cells of the   innate 
immune system. RA is characterized by the expansion of auto reactive T-cell 
clones that typically lack CD28. The  frequency of such CD4+CD28 null T cells 
correlates with disease   severity with respect to erosive progression  and   extra-
articular manifestations. The frequency in the RA with CAD cohort (median 3.5%) 
was higher than in historical controls of patients with RA and absence of extra-
articular manifestations, suggesting that CV co-morbidity in RA is  correlated with 
disease severity and that CD4+CD28null T cells  may be involved in the Cardio 
Vascular complications of RA. CD4+CD28nullT cells have been directly 
implicated in the pathogenesis of coronary artery disease. Persistent activation of 
such auto reactive cells in RA may result in a vicious cycle of cytokine  release, 
mononuclear cell activation and tissue injury.                                                                                 
However, we cannot exclude the possibility that  the high  CD4+CD28null T 
cells  levels in RA with CAD patients is reflective   of an increased RA disease 
 
 
severity  in these patients.  Addressing this issue further will require comparing RA  
patients that are matched for disease severity. 
The impact of severe RA on mortality may  be mediated via reduced 
physical activity that will compromise cardio respiratory fitness. This might 
contribute to higher Cardio vascular  mortality in RF-positive RA patients. 
Disability has been shown to be a predictor of all-cause and Cardiovascular 
mortality in early inflammatory polyarthritis and established RA.  
More severe RA is also associated with a  higher cumulative inflammatory 
disease burden. Atherosclerosis is now accepted to be an inflammatory condition, 
and elevation of inflammatory markers including high-sensitivity C-reactive 
protein (CRP) has been associated with the subsequent development of Cardio 
vascular events in the general population, and histological study has identified the 
presence of inflammatory cells in atherosclerotic plaque in the general population. 
If atherosclerosis is promoted by chronic low-grade  inflammation, as suggested by 
Ridker, it is plausible that atherosclerosis may be accelerated in chronic systemic 
inflammatory conditions like RA. A previous study of the Rochester RA cohort 
demonstrated that cumulative inflammation measured using the erythrocyte 
sedimentation rate (ESR) was associated with subsequent Cardio vascular events. 
In addition, modest elevations in baseline CRP were associated with subsequent 
 
 
Cardio vascular mortality in patients with early inflammatory polyarthritis who 
were registered with the Norfolk Arthritis Register.  
Effective drug therapy, which reduces inflammation in RA, has been shown 
to reduce all-cause and CVD mortality, and responders to anti-tumor necrosis 
factor-a therapies were found to have a lower incidence of myocardial infarction 
than  non-responders. Therefore RF-positive patients may have increased ischemic 
heart  disease mortality because they have increased levels of chronic 
inflammation, and suppression of this inflammation may lead to improved 
survival.  
Other factors associated with RF status and  severity of RA include anti-
CCP status and presence of the HLA-DRB1 shared  epitope. High titers of anti-
CCP predicted mortality in a study of RA patients in Finland. A recent study 
reported that, while RF status and anti-CCP status were each associated with 
mortality in inflammatory polyarthritis, possession of both markers did not confer 
a higher mortality risk. In addition there was a significant interaction between these 
3 variables in the models predicting mortality. Therefore mortality outcome in 
inflammatory arthritis appears to be associated with variables that promote more 
severe disease.  
It has been hypothesized that circulating immune complexes and RF might 
have a direct effect on endothelial cells to promote atherosclerosis. Dessein, et al 
 
 
reported that RF and interleukin 6 were associated with biomarkers of endothelial 
dysfunction in RA patients, even after adjusting for traditional CVD risk factors. 
Impaired nitrate-mediated vascular dilation was found to be associated with 
circulating levels of immune complexes in RA, and this has been suggested to be 
one of the mechanisms by which atherosclerosis is promoted in RA. It is 
interesting to note that B lymphocytes have been identified in atherosclerotic 
plaques of RA patients51, while in atherosclerotic plaques of non-rheumatoid 
patients T lymphocyte infiltration is observed. Therefore there is some modest 
evidence that RF may be involved in the pathogenesis of atherosclerosis in RA.  
Excess mortality in RA is largely confined to those who are RF-positive. It 
is still unclear whether RF itself contributes to the reduced life expectancy of 
patients with RA, or whether it is simply a marker for more severe disease and 
higher cigarette smoking exposure. Early use of disease modifying  antirheumatic  
drugs and use of biologic agents to suppress inflammatory disease is likely to 
influence the life expectancy of these patients, and it will be interesting to explore 
whether cardio vascular disease outcomes in patients treated with B cell 
suppression are improved. However, it is likely that a combined approach is 
required, with modification of lifestyle factors, as well as suppression of the 
inflammatory disease process, to improve the mortality outcome in RF-positive 
subjects.  
 
 
RA is characterized by chronic inflammation and hyperplasia of synovial 
tissue. More importantly, it is a quintessential systemic disease that can manifest in 
most major organ systems. T cells play a central role in the immunopathogenesis 
of RA and are the key regulators of the chronic destructive joint lesions. In 
addition, patients with RA have abnormalities in T-cell homeostasis that affect the 
entire pool of T cells. One of the consequences of dysregulated T-cell homeostasis 
is the emergence of large clonal CD4+CD28null T-cell populations that are auto 
reactive and cytotoxic, and infiltrate synovial tissue. The highest frequency of 
CD4+CD28null T cells is found in severe RA, particularly in patients with 
rheumatoid vasculitis. When the inflammatory process in RA spreads to extra-
articular sites, such as mid-size arteries and capillaries, morbidity and mortality are 
clearly increased. 
Because the chronic inflammatory process and immune dysregulation in RA 
have features in common with those involved in atherosclerosis, they could 
predispose patients with RA to accelerated CAD. Several studies have documented 
an increased risk of atherosclerosis and myocardial infarction in patients with RA. 
In addition, RA is associated with a reduced life expectancy, primarily because of 
excessive deaths from cardio vascular disease. RA is a heterogeneous disease, and 
the disease phenotype itself is predictive of mortality; patients with more severe 
clinical disease have higher mortality rates. Overall mortality is also increased in 
 
 
patients who are positive for the autoantibodies, rheumatoid factors. In addition, 
the extent of inflammation in RA has been linked to an increased risk of cardio 
vascular mortality. The number of swollen joints, independent of traditional cardio 
vascular risk factors, is predictive of cardio vascular related deaths among Pima 
Indians with RA. The strongest association with increased cardio vascular 
mortality is seen in patients with extra-articular manifestations of RA.                    
         Inflammation is part of the process of atherosclerotic disease, and patients 
with inflammatory diseases, such as rheumatoid arthritis and systemic  lupus  
erthymatosus, are at increased risk for cardiovascular events. Among patients with 
rheumatoid arthritis, testing positive for circulating rheumatoid factor (RF) 
represents an added risk for ischemic heart disease.RF may be present in 15% of 
the general population without clinical rheumatoid arthritis. This factor may be 
acquired through the presence of other autoimmune disease or previous bacterial 
infections. In addition, it appears that smokers have higher rates of testing positive 
for RF. The current study examines whether RF represents an independent risk 
factor for ischemic heart disease in a general population of patients.  
In the general population, the presence of advanced  atherosclerosis on 
angiography is predictive of a worse prognosis. The extent of atherosclerosis 
determined by angiography has not been studied in RA. Indirect evidence of 
accelerated atherosclerosis in RA comes from studies using carotid artery intima 
 
 
medial thickness as a marker of atherosclerotic burden and vascular risk. Increased 
intima-media thickness was independent of traditional Cardio vascular  risk factors 
but was related to RA disease activity, duration and severity.Data presented here 
suggest that the acceleration of atherosclerotic disease in RA holds for multiple 
vascular beds, lending support to a systemic disease mechanism. 
Patients with RA have a significantly higher prevalence of angina pectoris. 
Also, women with RA have a significantly increased risk of myocardial infarction 
compared with those without RA. This excess of Cardio vascular disease in RA 
cannot be explained by the traditional Framingham risk factors and probably arises 
from the underlying disease and/or its treatment. There is no evidence that disease-
modifying antirheumatic drug (DMARD) therapy increases mortality in RA. 
Corticosteroids can cause dyslipidemia, hyperglycemia and hypertension but may 
also control inflammation in RA. Studies have attempted to define the impact of 
steroids on mortality in RA but the results are inconsistent.DMARD treatment can 
actually improve the outcome in RA. Choi and colleagues have demonstrated that 
methotrexate-treated patients had a 70% reduction in CV deaths compared with 
those who did not receive disease-modifying therapy. Other DMARDs such as 
sulfasalazine, penicillamine, hydroxychloroquine, and gold did not confer this 
protection. Thus, the RA disease process itself likely contributes to accelerated 
CAD. 
 
 
The inflammatory mechanisms in RA may enhance atherogenesis in several 
ways. C-reactive protein, a useful marker of disease activity, is elevated in RA and 
has prognostic value. It may also participate directly in endothelial injury by 
sensitizing endothelial cells to T-cell mediated cytotoxicity. Circulating cytokines 
in RA, such as TNF-α, result in endothelial activation and up-regulation of 
adhesion molecules. Indeed, endothelial dysfunction is frequently present in RA 
patients, even in the absence of identifiable CV risk factors  and improves with 
anti-TNF-α therapy. Cytokines will also non-specifically activate monocytes and 
other cells of the innate immune system. RA is characterized by the expansion of 
auto reactive T-cell clones that typically lack CD28. The frequency of such 
CD4+CD28null T cells correlates with disease severity with respect to erosive 
progression and extra-articular manifestations. The frequency in the RA with CAD 
cohort (median 3.5%) was higher than in historical controls of patients with RA 
and absence of extra-articular manifestations, suggesting that CV co-morbidity in 
RA is correlated with disease severity and that CD4+CD28null T cells may be 
involved in the CV complications of RA.CD4+CD28null T cells have been directly 
implicated in the pathogenesis of coronary artery disease. Persistent activation of 
such autoreactive cells in RA may result in a vicious cycle of cytokine release, 
mononuclear cell activation and tissue injury.However, we cannot exclude the 
possibility that the high CD4+CD28null T cells levels in RA with CAD patients is 
 
 
reflective of an increased RA disease severity in these patients. Addressing this 
issue further will require comparing RA patients that are matched for disease 
severity but are disparate for CAD.                    
Patients with RA have a significantly higher prevalence of  angina pectoris. 
Also, women with RA have a significantly increased risk of myocardial infarction 
compared with those without RA. This excess of cardio vascular  disease in RA 
cannot be  explained by the traditional Framingham risk factors and  probably 
arises from the underlying disease and/or its treatment. 
There is no evidence that disease-modifying antirheumatic  drug (DMARD) 
therapy increases mortality in RA. Corticosteroids can cause dyslipidemia, 
hyperglycemia and  hypertension but may also control inflammation in RA. 
Studies  have attempted to define the impact of steroids on mortality in  RA but the 
results are inconsistent. DMARD treatment  can actually improve the outcome in 
RA. Choi and colleagues  have demonstrated that methotrexate-treated patients  
had a 70% reduction in CV deaths compared with those who  did not receive 
disease-modifying therapy. Other DMARDs  such as sulfasalazine, penicillamine, 
hydroxychloroquine, and  gold did not confer this protection. Thus, the RA disease 
process  itself likely contributes to accelerated CAD. The inflammatory 
mechanisms in RA may enhance atherogenesis  in several ways. C-reactive 
protein, a useful marker of disease  activity, is elevated in RA and has prognostic 
 
 
value.   It may also participate directly in endothelial injury by sensitizing  
endothelial cells to T-cell mediated cytotoxicity. Circulating cytokines in RA, such 
as TNF-α, result in endothelial   activation and up-regulation of adhesion 
molecules.  Indeed, endothelial dysfunction is frequently present in RA patients, 
even in the absence of identifiable CV risk factors   and improves with anti-TNF-α 
therapy.  
Cytokines will   also non-specifically activate monocytes and other cells of 
the   innate immune system. RA is characterized by the expansion of autoreactive 
T-cell clones that typically lack CD28. The   frequency of such CD4+CD28null T 
cells correlates with disease   severity with respect to erosive progression  and    
extra-articular  manifestations. The  CD4+CD28null T cells have been directly 
implicated in the pathogenesis of  coronary artery disease. Persistent activation of 
such autoreactive    cells in RA may result in a vicious cycle of cytokine   release, 
mononuclear cell activation and tissue injury.However,  we cannot exclude the 
possibility that the high   CD4+CD28null T cells levels in RA with CAD patients is 
reflective  of an increased RA disease severity in these patients. Addressing this 
issue further will require comparing RA patients that are matched for disease 
severity but are disparate  for  CAD. 
 
 
 
SYSTEMIC LUPUS ERTHTYMATOSUS 
  Atherosclerotic disease is common in systemic lupus erthymatosus  and is 
the result of multiple pathogenic mechanisms that include traditional risk factors as 
well as SLE-related factors. Endothelial dysfunction and arterial stiffness 
contribute significantly to the  Atherogenic process  Accelerated atherosclerosis is 
a significant cause of morbidity and mortality in systemic lupus erthymatosus. 
Both arteritis and atherosclerosis can involve the coronary arteries of young  
patients suffering from SLE. Coronary arteritis, though rare, occurs in association 
with active vasculitis in other organs  such as skin, spleen, kidneys, etc. Coronary 
spasm  in SLE patients is rare, and  when it occurs, it is usually in relation to the 
two common  pathological processes   mentioned above. 
Systemic lupus erthymatosus is an autoimmune disorder affecting multiple  
organ systems. Patients with systemic lupus erthymatosus exhibit a bimodal  
pattern of mortality, with those who have had the disease for 5 to 10 years  being at 
increased risk of cardiovascular disease,particularly myocardial  infarction. 
Elevated levels of conventional cardiovascular risk factors  promote vascular 
damage resulting in impairment of normal endothelial  function. In addition, 
autoantibodies directed against oxidized lipoproteins, along with chronic secretion 
of inflammatory cytokines and suppression of  fibrinolytic parameters, are thought 
to increase atherogenesis. It is no longer a matter of dispute that SLE patients have 
 
 
an increased risk of developing atherosclerotic cardiovascular disease, particularly  
before the age of 50. The incidence of coronary heart disease in women with SLE 
aged 35–44 years has been estimated to be 50- fold greater than in the general 
population, and the cumulative   prevalence of CAD in SLE patients was 8.9%. 
Early detection and management  of  atherosclerosis may reduce the morbidity and  
improve the survival of patients with SLE. 
Coronary artery vasculitis remains an infrequent complication of SLE. Prior 
to the widespread use of coronary angiography, coronary vasculitis was a post 
mortem diagnosis. Coronary angiography has helped in evaluating patients with 
suspected coronary vasculitis. It has been suggested that a rapid rate of progression 
of coronary lesions is more suggestive of a vasculitic process and, therefore, single 
angiographic studies may be inadequate. One case report documented a tertiary 
referral center experience where only two patients younger than  35 years of age 
with coronary vasculitis were identified over a period of 40 years.  A possible 
mechanism of arterial injury in SLE might be the development of auto-antibodies 
that may target the heart or the blood vessels.  According to Dangas et al., there are 
increased auto-antibodies against actin and myosin during and after an acute 
coronary syndrome. The present case represents only the fourth case reported in 
detail with SLE and coronary artery disease in a patient younger than 21 years old. 
The diagnosis of coronary vasculitis secondary  to SLE in this case is suggested by 
 
 
the documentation of the diagnosis of SLE, the absence of classic risk factors for 
atherosclerotic heart disease (no evidence of diabetes, hypertension, family history 
of CAD or smoking) and the occurrence of angina pectoris or myocardial 
infarction at a young age. 
In addition to premature coronary artery disease, there was clearly a rapid 
change in the patient’s anatomy after coronary artery bypass graft surgery with 
total occlusion of 3 out of 4 grafts over only a 4-month period. The fourth graft 
displayed segmental narrowing. This is higher than early occlusion rates reported 
in multiple trials. Also, the internal mammary artery of our patient displayed areas 
of fibrosis and intimal thickening per the operative report,precluding its use as a 
graft. These events suggest vasculitis as a possible etiology for her deterioration, as 
is suggested from the pathology slide. Immune complex deposition in the coronary 
artery walls in patients with SLE have been documented via immunofluorescence 
studies and the relationship between inflammatory immunologic injury and 
atherosclerosis has been demonstrated experimentally. Similar immune complex 
deposition in coronary vessels of SLE patients may predispose to intimal 
thickening and atherosclerosis, thus increasing the frequency of myocardial 
infarction. Histologic findings at autopsy have  displayed both neutrophilic and 
lymphocytic infiltration, fibrinoid necrosis  and immune complex deposition. 
 
 
The etiology of the accelerated atherosclerosis in SLE in not  known, but it 
has been linked to inflammation and endothelial dysfunction, a consequence of the 
inflammatory process. Flow-mediated dilatation is a non-invasive method of 
measurement  of endothelial dysfunction. It is based  on the change  in diameter of 
a conduit artery in response to increased flow, typically induced by a period of 
ischemia in the distal circulatory bed.  
The formation of immune complexes in patients with SLE  is strongly 
associated with acceleration of atherogenesis.The presence of autoantibodies to β2-
glycoprotein-1 and  HDL-associated  protein and major antigen for anticardiolipin 
antibodies, is  strongly associated with  inflammation in patients   with  SLE  as are 
autoantibodies to components of oxidized  LDL. In patients with SLE, immune 
complexes activate  complement, which in turn acts on mast cells and basophilsto 
release vasoactive amines. These amines, which include   histamine and 5-
hydroxytryptamine, promote endothelial cell retraction and increased vascular 
permeability, induce   the expression of  endothelial adhesion molecules, and  
attract polymorphs that subsequently infiltrate the area of  damage Thrombin and 
inflammatory cytokines such as  interleukin-1, interleukin-6, and tumor necrosis 
factor–α  are also involved in this process. Following the trigger of adhesion 
molecule expression, preformed P-selectin is rapidly but transiently translocated to 
the endothelial surface, and within hours E-selectin is  also expressed . 
 
 
Subsequently, integrin molecules on  the leukocytes bind to immunoglobulin 
superfamily  receptors. For example, β2-integrins bind to intercellular   adhesion 
molecule–1, and monocyte α4β1 integrin binds to  vascular cell adhesion 
molecule–1 (VCAM-1).  These  molecules promote the capture and rolling of the 
leukocytes. Pro-oxidant molecules stimulate endothelial nuclear  factor κB (NF-
κB), thereby promoting expression of  VCAM-1 and monocyte chemotactic 
protein–1 (MCP-1), and subsequently monocyte infiltration, by interaction with 
platelet-endothelial cell adhesion molecule.  In diabetic  patients, advanced  
glycosylation   endproducts also  mediate  prolonged expression of    NF-κB, and 
may be a mechanism  for the similar increased risk of cardiovascular   
complications.28 Nitric oxide induces the endogenous  inhibitor of NF-κB,  IκBα, 
which reduces expression of  both VCAM-1 and MCP.  
Advances in medical therapy and a better understanding of systemic lupus 
erythematosus (SLE) have contributed to a dramatic improvement in the long-term 
survival of patients. However, despite the overall long-term improvement, 
coronary artery disease remains a major cause of  morbidity and mortality  with an 
incidence that is approximately nine-fold greater than would be expected for this 
population.  Following active lupus, coronary artery disease is the second most 
common cause of hospitalization for SLE patients.  Manzi et al. found that, when 
controlled for age and gender, women with SLE who are 35–44 years old have a 
 
 
50-times higher risk of myocardial infarction (MI).  Previous autopsy studies have 
observed that severe coronary artery disease is present in as many as 40% of 
patients with SLE compared with only 2% of age-matched controls at the time of 
death.                                          
Etiologies of myocardial damage in SLE patients include premature 
atherosclerotic disease,  antiphospholipid antibody syndrome,8 coronary artery 
spasm,  coronary artery vasculitis  and restenosis after percutaneous 
revascularization procedures. The present case illustrates the importance and 
challenge of differentiating among these etiologies, especially since the therapies 
used are different in each situation. The following discussion ill focus on the 
diagnosis and pathogenesis of coronary artery disease with an emphasis on 
premature atherosclerosis and coronary vasculitis in patients with SLE. 
ANTIPHOSPHOLIPIDS ANTIBODY SYNDROME 
The antiphospholipid syndrome (APS) is an acquired thrombotic disorder 
characterized by recurrent venous or arterial thrombosis or recurrent miscarriages, 
or both, associated with the presence in the serum of IgG or IgM anticardiolipin 
antibodies (aCL) and/or lupus anticoagulant (LAC). APS may occur as a primary 
disorder (PAPS) or associated with connective tissue diseases, mainly systemic 
lupus erthymatosus (secondary APS).Primary and secondary APS are both 
associated with a significant increase of cardiovascular risk.  
 
 
Atherosclerosis is an autoimmune/inflammatory disease associated with 
infectious, inflammatory, and autoimmune factors. Both humoral and cellular 
immune mechanisms have been proposed to participate in the onset and/or 
progression of atheromatous lesions. Heat-shock protein (hsp), oxidized low-
density lipoprotein (LDL), and beta2-GPI have been reported to elicit humoral and 
cellular immune response in both experimental animals and humans. 
Antiphospholipid (antibody) syndrome  is a pathological condition that is 
also referred to as "Hughes syndrome." It originates from excess accumulation of 
blood clots by antiphospholipid  antibodies. The syndrome may occur as a  primary 
condition (primary APS) or along with  the autoimmune disease, systemic lupus 
erthymatosus. SLE is a chronic disease that affects certain organs, blood vessels, or 
the  skin. The main signs of APS include blotchy  skin, migraine, memory loss, 
fatigue, deep vein   thrombosis, pulmonary embolism, and stroke. Primary APS 
may affect heart valves and present with such damage in 30% of patients. In  
pregnant women with APS, miscarriages may occur. In this overview, we present 
an up-to-date description and synthesis of the main vascular   ischemic (occlusive) 
diseases  with neuropsychiatric  symptomatics in APS. The recognition that a 
number of SLE manifestations have a  thrombotic rather than an  inflammatory 
basis can  be considered one of the most important recent contributions to 
rheumatology and immunology. The "anticardiolipin syndrome" described by   
 
 
Graham Hughes in the 1980s,1 which was subsequently renamed antiphospholipid 
(Hughes) syndrome, appeared as a frequent condition in  patients with SLE2 but 
also was present in others without SLE or other autoimmune diseases. In  such 
cases it was termed a "primary" APS (PAPS). Almost 20 years after its definition, 
APS has crossed over into many fields of medicine. However, the full spectrum of 
the  syndrome has yet  to be defined, and significant advances in the diagnosis and 
management of patients with APS  have been made. In addition, a consensus about  
very important questions, such as the use of alternative tests for anticardiolipin 
(aCL) antibodies  and lupus anticoagulant (LA) assays, the  treatment of pregnancy 
failure, or the intensity of anticoagulant therapy, has not yet been  achieved.  
These autoantigens are expressed within atherosclerotic lesions. 
Immunization with the given autoantigens elicits an immune response that 
influences lesion progression. Atherosclerosis susceptibility can be transferred by 
autoantigen-sensitized lymphocytes from immunized animals. Patients with 
systemic lupus erthymatosus (SLE) and antiphospholipid syndrome (APS) have a 
high risk for atherosclerotic cardiovascular events. The traditional risk factors fail 
to fully account for accelerated atherosclerosis in SLE and APS. Immunological 
alterations, such as antibodies to oxidized LDL, antiphospholipid antibodies (aPL), 
antibodies to beta-2 Glycoprotein (anti-beta2-GPL), anti-prothrombin antibodies, 
may play a role in premature atherosclerosis in SLE and APS.  aPLs predict an 
 
 
increased risk for MI, and their levels are increased in young survivors of MI. 
ß2GP1 is a cofactor for antibody binding to cardiolipin,and recent studies indicate 
that many  aCLs  recognize oxidized CL  (OxCL) and/or adducts of   OxCL with 
ß2GP1. The antiphospholipid antibody syndrome is characterized by both   arterial 
and venous thrombosis and is common in SLE.  In the present study, lupus 
anticoagulant showed a significant association with IHD in  SLE. In addition, both 
aCLs and anti-ß2GPI antibodies tended to be associated with arterial disease in 
SLE. It is possible, therefore, that the increased risk of  IHD in SLE is to some 
extent caused. 
It is assumed that aPL are a significant risk factor for AMI in selected 
patients. According to Adler et al, aPL precede the infarction, rather than follow it. 
The results we obtained regarding the frequency of APS in AMI (38%) are a little 
higher, as compared with authors cited above. This could be attributable to proper 
initial selection of patients, suspected for APS. The increased values of ACA, 
ß2GP1 antibodies and CD31 registered in patients with AMI correlate well with 
the development of arterial thrombosis, and some disputable pathogenic 
mechanisms of arising of hyper coagulation in patients with APS. According to 
Galli et al, the presence of ACA and ß2GP1 antibodies in patients with systemic 
lupus erthymatosus is connected with a risk for development of arterial thrombosis. 
Many authors consider ß2GP1, which is the main co-factor of binding between 
 
 
ACA and cardiolipin, as one of the key structures. On the other hand, a direct 
formation of antibodies against ß2GP1 is also observed in APS. The importance of 
ß2GP1 is connected with its functions of a natural coagulant, namely the blocking 
of the contact system of coagulation , inhibition of adenosin diphosphate-
depending aggregation and the synthesis of factor Xa from the activating platelets, 
as well as the inhibition of prothrombinase activity of inactivated platelets .  
Recently, there are reports that in patients with secondary APS, antibodies against 
ß2GP1 can be used as a target for immune mediated atherogenesis. Anti- ß2GP1 
antibodies can trigger other mechanisms - to activate the endothelium cells and 
activate adhesion molecules such as ICAM-1, VCAM-1, and E-selectine. 
The arising of thrombosis in APS is also associated with increased activity 
of thrombotic endothelium adhesion molecules CD31.  CD31 is expressed on 
platelets, neutrophils, monocytes and endothelium cells, and it plays a significant 
role in their interaction. Apart from the signal function it has,CD31 also activates 
the ß-3 subgroup of integrins, which in turn play a crucial role in the adhesion of 
cells. It is not by chance that the flowcytometric investigation of the expression of 
CD31 on the circulating platelets is recommended as an important method for 
investigating thrombotic conditions. The results we obtained of increased 
expression of the marker in the chronic stage of myocardial infarction correlate 
 
 
well with the observation in cases of following thrombosis, and they prove the 
significance of CD31 in the pathogenesis of APS. 
In conclusion, we consider that the investigations we carried out confirm the 
proposition that aPL play an important role in the pathogenesis of acute coronary 
incidences. The timely diagnosis of APS could improve the prognosis, prevention 
and treatment of patients in this risk group. 
 
                                      
                                            
 
 
 
 
 
 
 
 
 
 
MATERIALS 
SUBJECTS: 
Patients who are all   positive to Rheumatoid    factor attending   Govt. 
General Hospital between May 2006—may2008 
PERIOD  OF STUDY: 
May2006—may 2008 
DESIGN  OF STUDY 
Cross sectional  observational study  
ELIGIBILITY CRITERIA 
All patients with  RF positive by ELISA           
INCLUSION CRITERIA 
         1. Hypertension 
         2. Obesity 
         3. Diabetes mellitus 
         4. H/O smoking, 
         5. H/o IHD 
         6. Family h/o IHD 
 
 
 
EXCLUSION CRITERIA  
                    1. Chronic infection 
                    2. Elderly patients (>60 years)  
                    3. Patients with thyroid abnormality 
 
    
 
 
                      
 
                               
 
 
 
 
 
 
 
 
METHODOLOGY 
One hundred patients with rheumatoid arthritis and who were positive for  
RF  attending  Govt.General Hospital   during the study period  evaluated for  IHD  
by ECG and ECHO. 
Those  who are included  in  the  study were evaluated for traditional  risk 
factors h/o Diabetes, smoking ( in the past / present) family h/o IHD and they were 
clinically examined for hypertension ,body mass index for Obesity and  features of 
RA. Pt with BP >140/90 mmhg were  considered as hypertensives in this study. 
Fasting blood  for sugar and lipid profile were measured. They were also evaluated  
for RF titres  by ELISA. A resting 12 lead ECG  was carried out for features of 
IHD. The following changes in the ECG were taken as marker of ischemia                                  
1) The combination of ST elevation  in a set of leads and reciprocal      
             ST depression in a set of leads.  
      2) Inversion of T with ST still being elevated. 
          3) Presence of pathological Q waves                                  
Statistical analysis:                                    
Statistical analysis was done using standard formulae  SPSS(Statistical Package for 
social sciences) in windows Dos version. Base line data like age, gender, RF, 
Traditional risk   factors were collected. Patients were categorized  on their RF 
positive with or without traditional risk factors and Ischemic changes. 
 
 
                                    The significance of  Association between the factors   
was collected using PEARSON  CHI-SQUARE TEST and YATES Corrected  
CHI-SQUARE TEST. P<0.05 was taken as significant.     
 
 
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRITERIA CONSIDERED IN THE STUDY 
 
S.NO 
 
PARAMETERS 
 
VALUES 
 
1 
 
2 
 
3 
         
4 
 
 
 
 
 
 
 
 
         
5 
 
 
 
 
 
 
 
 
       Obesity 
 
       Hypertension: 
 
       Diabetes -Fasting blood suger 
 
 Abnormal Lipid profiles; 
 
            VLDL: 
 
             LDL: 
 
             HDL: 
     
             TGL: 
 
Rheumatoid factor; 
 
                 Low titre: 
 
                 High titre: 
 
 
 
 
>23 
 
>140/90mmhg 
 
> 110               
 
 
 
       >100 mg/dl 
 
       >100mg/dl 
 
       <40mg/dl  
 
       >160mg/dl            
 
 
 
       <320IU/ml 
 
       >320IU/ml 
 
 
 
         
 
 
 
                      OBSERVATIONS AND RESULTS   
     
 
1. 
 
 
 
 
 
 2. 
 
 
 
 
 
 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL NUMBERS OF PATIENTS(n) 
 
                                             FEMALE 
 
                                                  MALE 
 
AGE 
 
                                                       <40YEARS 
 
                                                     40-60YEARS 
 
ECG-ISCHEMIC CHANGES 
                                                    TOTAL 
 
                  A. WITH TRADITIONAL FACTORS 
 
                                                             MALE 
 
                                                            FEMALE 
 
 
                 B. ONLY RF POSITIVE 
 
                                                           MALE 
 
                                                        FEMALE 
 
                                                    HIGH TITRE- RF 
 
                                                     LOW TITRE-RF 
 
 
 
 
 
           :100 
 
:65 
 
:35 
 
 
 
             :43 
 
              :57 
 
              
             :16 
 
              :12 
 
              :7 
 
              :5  
 
 
              :4 
 
              :4 
 
              :0 
 
              :3 
 
              :1            
 
 
 
 
 
AGE DISTRIBUTION 
           Of  the  hundred patients with RF positivity , there were 65  
females and 35 males, age distribution of those included in the study are showed in  
table no:1 
TABLE NO-1 AGE DISTRIBUTION IN RELATION TO SEX 
AGE 
 
MALE FEMALE 
<20 
 
0 2 
20-30 
 
5 12 
30-40 
 
7 17 
40-50 
 
20 30 
50-60 
 
3 4 
 
CHART NO-1 AGE DISTRIBUTION IN RELATION TO SEX 
0
5
10
15
20
25
30
35
<20years 20-30 30-40 40-50 50-60
male
female
 
 
 
TABLE -2:  ISCHEMIC CHANGES IN ECG IN RELATION TO 
PRESENCE OF RF AND TRADITIONAL RISK FACTORS 
DISTRIBUTION OF PATIENTS SHOWING ISCHEMIC CHANGES ECG 
 
RF with traditional risk factor 
 
RF without Traditional risk factor 
N=12 (75%) 
 
N=4 (25%) 
 
M-7(43.75%) F-5(31.25%) 
 
M-4(25%) F-0 
 
CHART-2 : ISCHEMIC CHANGES IN RF POSITIVE PATIENTS 
 
 
84
16
TOTAL NUMBER OF PATIENTS-100 
NO ECG CHANGES
ECG CHANGES
 
 
TABLE NO-3: SEX DISTRIBUTION OF  ISCHEMIC CHANGES IN 
RELATION TO RF TITRES WITH TRADITIONAL RISK FACTORS 
 
ISCHEMIC CHANGES IN ECG(N=16) 
 
MALE(11) 
 
FEMALE(5) 
RF-HIGH TITRE 
 
         6  (37-5%) 
 
RF-LOW TITRE 
 
         5  (31.25%) 
RF-HIGH TITRE 
 
          2  ((12.5%) 
RF-LOW TITRE 
 
        3  (18.75%) 
 
CHART-3: ISCHEMIC CHANGES INRELATION TO RF TITRE WITH 
AND WITHOUT TRADITIONAL RISK FACTORS 
 
In the present study there were 16 patients who had  RF positivity with 
Ischemic changes in ECG.11 were males and 5 were females.Of these 6 males and 
2 females had high titre of RF with ischemic changes.                          
 
 
Considering the association of traditional risk factors as an additional  factor 
with RF positivity,12 had ischemic changes. There were 4 males who had only RF 
positivity without traditional risk factors. 
TABLE -4: AGE AND SEX DISTRIBUTION IN RELATION TO 
ISCHEMIC CHANGES OF RF WITH TRADITIONAL RISK FACTORS 
AGE DISTRIBUTION OF ISCHEMIC CHANGES 
 
AGE MALE FEMALE 
 
<20 0 0 
 
20-30 1    (6.25%) 0 
 
30-40 4    (25%) 1 (6.25%) 
 
40-50 4    (25%) 2 (18.75%) 
 
50-60 2   (12.5%) 1 (6.25%) 
 
 
TABLE -5: AGE  DISTRIBUTION IN RELATION TO 
ISCHEMIC CHANGES OF RF WITH TRADITIONAL RISK FACTORS 
 
 
             
  
χ2=1.19 
 P=0.28  NOT SIGNIFICANT 
ECG-ISCHEMIC CHANGES 
AGE NUMBERS PERCETAGE 
  
40 yrs           6 37.5% 
 41-60yrs          10 62.5% 
 
 
On comparing below 40age : 40-60age  1:1.66   ratio by chi square test, the 
P value is 0.28 which is > 0.05.so,it is not significant. The association between age 
distribution in RF positive patients is not significant.  
CHART -4: AGE  DISTRIBUTION IN RELATION TO 
ISCHEMIC CHANGES OF RF WITH TRADITIONAL RISK FACTORS 
 
TABLE-6: SEX DISTRIBUTION IN RELATION TO ISCHEMIC 
CHANGES  DUE  TO  RF WITH TRADITIONAL RISK FACTORS 
 
ECG-ISCHEMIC CHANGES 
                   SEX NUMBERS PERCENTAGE 
  
MALE 11 (35) 31.4% 
   
FEMALE 5 (65) 7.7% 
                                   χ2= 9.53 / P=0.002 SIGNIFICANT 
 
 
31.4%  of male and 7.7% of females with  RF positive with traditional risk 
factors  had  ischemic changes . On comparing the female, male ratio  (2.2 :1) by 
chi square test, the P value is  0.002. This indicating that males with RF and 
traditional risk factors  have greater risk of  IHD compared to females.                       
CHART-5: SEX DISTRIBUTION IN RELATION TO ISCHEMIC 
 CHANGES  DUE  TO  RF WITH TRADITIONAL RISK FACTORS 
0
10
20
30
40
50
60
70
ECG CHANGES NO ECG CHANGES
MALE
FEMALE
 
TABLE-7: SEX DISTRIBUTION OF ISCHEMIC CHANGES IN 
 
RELATION TO RF TITRES WITH TRADITIONAL RISK FACTORS 
 
ISCHEMIC CHANGES IN ECG(N=16) 
 
MALE(11) 
 
FEMALE(5) 
RF-HIGH TITRE 
 
6  (37.5%) 
 
RF-LOW TITRE 
 
5  (31.25%) 
RF-HIGH TITRE 
 
2  ((12.5%) 
RF-LOW TITRE 
 
3  (18.75%) 
 
 
 
 
CHART-6: SEX DISTRIBUTION OF  ISCHEMIC CHANGES IN 
 
RELATION TO RF TITRES WITH TRADITIONAL RISK FACTORS 
 
TABLE-8:  ISCHEMIC CHANGES IN RELATION TO RF WITH AND 
WITHOUT TRADITIONAL RISK FACTORS IN PERCENTAGE. 
ECG-ISCHEMIC CHANGES(N=16) 
TRADITIONAL RISK    
FACTORS NUMBERS PERCENTAGE 
PRESENT  
12 75% 
 
NOT PRESENT 
 
4 25% 
                                  χ2= 22.3 ; P=0.001   SIGNIFICANT  
 
 
Of  this ischemic changes in RF positive with traditional risk factors  are 
44.4 % without traditional risk factors are 5.5 % . On comparing  these 3:1 ratio by  
chi square test , P value is 0.001which is statistically significant.  
CHART-7:  ISCHEMIC CHANGES IN RELATION TO RF WITH AND 
WITHOUT TRADITIONAL RISK FACTORS . 
 
TABLE- 9:  SEX DISTRIBUTION IN  RELATION TO ISCHEMIC 
CHANGES IN LONE RF POSITIVE AND TITRES 
 
ISCHEMIC CHANGES IN ECG(N=4) 
 
MALE(4) 
 
FEMALE(0) 
RF-HIGH TITRE 
 
3 (75%) 
 
RF-LOW TITRE 
 
1  (25%) 
RF-HIGH TITRE 
 
0 
RF-LOW TITRE 
 
0 
          
 
 
CHART-8 :  ISCHEMIC CHANGES IN ECG RELATION TO 
LONE RF POSITIVE AND TITRES                      
12
3
1
WITH TRADITIONL RISK 
FACTORS
RF-HIGH TITRE
RF-LOW TITRE
 
Lone RF without traditional risk factors was seen in only 4 male 
patients.there were no female patient .Of the 4 male patients 3 had high titre RF 
(>350). 
In men                     
            4/35 ==11.495%                    
                       CONFIDENCE INTERVEL= 4 – 28  
                   χ2YATES CORRECTED    P=0.01  SIGNIFICANT 
In study population 
                   4/100== 4% 
                 CONFIDENCE INTERVEL= is 1.7-5.4. 
                 χ2YATES CORRECTED    P=0.01  SIGNIFICANT                                                                        
 
 
                                                  DISCUSSION                                                                               
  In the study population, most of  the  RF positive patients clustered between 
30-50 years. Dividing the study population with  ischemic changes by ECG, by  
age, 6%  were   below 40 years and 10% were above  40 years. All of the above 
patients had RF positivity along  with traditional risk factors  and  ischemic 
changes in the ECG. 
In this  study  35% were males and  65% were females. The M:F ratio was 1: 
1.8.     16 patients had   ischemic changes in ECG constituting 11males (31.1%) 
and 5 females (7.7%)patients. This is concordant with  Edwards  C J et al1 where  
the M:F ratio was 1 : 1.02 . Comparatively females were more common in present 
study population. This is  because the patients selected  were  suffering RA which 
is more common in females. Considering the ischemic changes, males were 
affected  more than females though more number of  female patients were  
included in the study. This is also  similar to Edwards  C J et al1                              
Evaluating the 16%(n=16) who were RF  positive  with Ischemic changes 12 
patients  had traditional risk factors(75%).The other 4 patients had only RF 
positivity without any other risk factor. All these 4 patients were males. This 
indicates an association  of  RF and IHD a strong possibility especially in males.  
Among the 11male patients who had RF positivity with traditional risk 
factors  and ischemic changes, 6 patients had  high titre of RF and 5 patients had 
 
 
low titre. Percentage wise  37.5%  and  31.25% were having  high and low titres of  
RF along with traditional risk factors  causing IHD. This is concordant  with both 
Edwards  C J et al1, Kenneth J Warrington  et al4. 
Among the 5female patients  who had RF positivity with traditional risk 
factors , 2 patients  had ischemic changes with high titre of RF  making up  12.5%. 
3 patients had ischemic changes with low titre RF and traditional risk factors  
forming 18.75% This is disconcordant  with  both Edwards C J et al1, Kenneth J 
Warrington  et al4. 
By these data we can conclude, RF with traditional risk factor  have 
increased incidence of  ischemic changes in males than females especially high 
titre RF.         
In this study  only 4 patients had  RF positivity without traditional risk 
factors  along with ischemic changes and all of them were males.This is  36.3% of  
the total RF positive males in study population and 11.495% total male patients. 
No female patients had lone RF without traditional risk factor. This study is in 
concordance with Edwards  C J et al1  
The  long term Herfordshire  Cohort  study reported by  Sydall H E et al5 
had similar results. RF positive male patients  without  traditional risk factors are 
vulnerable to IHD. Females with traditional risk factors did not have IHD – this is 
discordant with this study. Our study indicated that IHD may be associated  with  
 
 
RF and traditional risk factors in females which is as in the study of  Sydall H E et 
al5 
Of these 4 male patients, 3 patients had  high titre of  RF positivity  which is 
75% and one patient had  low titre of  RF which is 25% .This  suggested that a 
high titre of RF may have  an increased incidence of IHD. This  concurs with  the 
earlier study by  Edwards  C J et al1  and del  Puente A et al3              
In this study, Autoantibody RF which is risk factor for IHD in men is 
11.495% (4 out of 35); confidence interval(CI)  is  4-28   and  4% (4out of 100)  
study population;  This   goes  with many  other similar  studies from various parts  
of the world. 
Most of the of  the studies state the  prevalence  to be  between  4-28%. 
Edwards  C J et al1- 11.6%( in men), Kenneth J Warrington1 et al4 -1.97% (in 
general population). 
From the observation and analysis of study  assumed that there is an 
association between high titre of RF and IHD.This association was significantly 
more in  male patients.                               
This study has a number of  potential limitations. The most important is the 
fact that this is a cross-sectional study  and  will  need confirmation by  a 
longitudinal cohort study.                                     
 
 
 
CONCLUSIONS 
¾ RF per se can be considered as one of the risk factor for Ischemic heart  
      disease in males. 
¾ High titre RF  alone can  further increase the Incidence of IHD. 
¾ RF associated with traditional risk factors increase the prevalence of  
IHD. 
¾ Though more female patients have positive RF ,they are not vulnerable to  
IHD 
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                                   PROFORMA 
Name: 
Age: 
Sex: 
OP No. 
Address: 
Presenting Complaints:- 
H/o HT  
H/o Diabetes Mellitus 
H/o IHD 
H/o Smoking  
Family H/o IHD 
Rhematalogical H/O 
EXAMINATION: 
           Pulse:                             
           BP: 
          CVS: 
           RS: 
           P/A: 
           CNS: 
 
 
INVESTIGATIONS:       
             BLOOD GLUCOSE: 
                      Fasting 
                      Post prandial  
             S.LIPID PROFILE:                        
                     TOTAL CHOLESTROL 
                     VLDL 
                     LDL 
                     HDL 
                     TGL     
             BODY MASS INDEX : 
             RHEUMATOID FACTOR: 
                    High titre 
                    Low titre 
            ELECTROCARDIOGRAM: 
            ECHO : 
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MASTER CHART 
S.no Name Age Sex 
Rheumatoid  
arthritis 
Traditional  
risk factor 
Rheumatoid  
factor 
Ecg-ischemic 
Changes 
Echo 
abnormality 
1 SELVI 25 F YES NO LT NO NO 
2 RUKUMANI43 43 F YES NO LT NO NO 
3 SARASWATHY 46 F YES NO HT NO NO 
4 JEYASEELI 32 F YES YES LT NO NO 
5 THANGASAMY 48 M YES NO LT NO NO 
6 THARA 45 F YES NO LT NO NO 
7 ELCY SELVAKUMAR 28 F YES NO HT NO NO 
8 MUNUSAMY 51 M YES YES HT YES YES 
9 ZARINA 19 F YES NO LT NO NO 
10 VELMURUGAN 35 M YES NO LT NO NO 
11 PAULRAJ 45 M YES NO LT YES YES 
12 PUNITHA 36 F YES NO HT NO NO 
13 SANCHAMMAL 45 F YES NO LT NO NO 
14 MURUGAMMA 42 F YES NO LT NO NO 
15 GANESH 43 M YES YES LT NO NO 
16 SANTRA 33 F YES NO HT NO NO 
17 KRISNAVENI 50 F YES YES LT YES NO 
18 KANCHANA 28 F YES NO HT NO NO 
19 GURUPRAKASH 48 M YES NO LT NO NO 
20 RAJESWARI 32 F YES NO LT NO NO 
 
 
S.no Name Age Sex 
Rheumatoid  
arthritis 
Traditional  
risk factor 
Rheumatoid  
factor 
Ecg-ischemic 
Changes 
Echo 
abnormality 
21 SEKAR 46 M YES YES LT NO NO 
22 ANJALAI 28 F YES NO LT NO NO 
23 GURUNATHAN 38 M YES NO HT YES YES 
24 PRIYA 19 F YES NO LT NO NO 
25 MOHANA 27 F YES NO LT NO NO 
26 SARATHA 50 F YES NO LT NO NO 
27 VASANTHA 45 F YES NO HT NO NO 
28 DHANABALAN 41 M YES NO LT NO NO 
29 VANITHA 50 F YES YES LT YES YES 
30 VEDHAM 45 M YES NO LT NO NO 
31 DHAMODHARAN 50 M YES NO LT NO NO 
32 VIMALA 40 F YES YES HT YES YES 
33 KRISNAMOORTHY 21 M YES NO LT NO NO 
34 SELVAKUMAR 40 M YES YES HT NO NO 
35 SABANBEGAM 25 F YES NO LT NO NO 
36 SUNDARI 40 F YES YES LT YES YES 
37 KUPPUSAMY 43 M YES  NO LT NO NO 
38 GANESHARANI 39 F YES NO LT NO NO 
39 SHAJITHABEGAM 45 F YES NO LT NO NO 
40 PREMA 50 F YES NO HT NO NO 
41 PANCHATCHARAM 48 M YES NO LT NO NO 
 
 
S.no Name Age Sex 
Rheumatoid  
arthritis 
Traditional  
risk factor 
Rheumatoid  
factor 
Ecg-ischemic 
Changes 
Echo 
abnormality 
42 BASKAR 46 M YES YES LT YES YES 
43 RAHGMATHNISHA 40 F YES NO HT NO NO 
44 RAJENDRAN 45 M YES YES LT NO NO 
45 RAJASEKAR 48 M YES NO HT YES YES 
46 BHUVANESWARI 40 F YES YES LT NO NO 
47 INDRA 42 F YES NO HT NO NO 
48 MEENA 40 F YES NO LT NO NO 
49 KUMARAPPAN 42 M YES YES LT YES YES 
50 THENMOZHI 36 F YES NO HT NO NO 
51 LAKSMI 33 F YES NO HT NO NO 
52 VARADHARAN 52 M YES YES LT NO NO 
53 SARASU 41 F YES NO LT NO NO 
54 HARIHARAN 41 M YES NO LT NO NO 
55 SHUNMUGAM 32 M YES NO HT YES YES 
56 RAMANAN 32 M YES NO LT NO NO 
57 AMIRTHARAJ 39 M YES YES LT NO NO 
58 SEETHA 43 F YES NO LT NO NO 
59 GRACEMARY 26 F YES NO LT NO NO 
60 ANURADHA 35 F YES NO HT NO NO 
61 JAYANTHY 30 F YES NO LT NO NO 
62 RANI 32 F YES NO LT NO NO 
 
 
S.no Name Age Sex 
Rheumatoid  
arthritis 
Traditional  
risk factor 
Rheumatoid  
factor 
Ecg-ischemic 
Changes 
Echo 
abnormality 
63 ARULSELVAN 23 M YES NO LT NO NO 
64 MOHAMMED IBRAH 38 M YES YES LT YES YES 
65 MEENATCHI 34 F YES NO LT NO NO 
66 SALIMABEE 45 F YES NO HT NO NO 
67 VEDHAVATHI 25 M YES NO LT NO NO 
68 GOWRI 44 F YES NO HT NO NO 
69 KRISHNAN 50 M YES YES LT NO NO 
70 KOMALAM 28 F YES NO LT NO NO 
71 NAGABHOOSNAM 48 F YES NO LT NO NO 
72 SAROJA 45 F YES YES HT YES YES 
73 SHAMSATHBEGAM 35 F YES NO LT NO NO 
74 KOKILA 37 F YES NO LT NO NO 
75 PITCAIMUTHU 51 M YES YES LT YES YES 
76 PRAKASAM 42 M YES YES LT NO NO 
77 MANGARYARKARASI 45 F YES NO LT NO NO 
78 KAMATCHI 40 F YES NO LT NO NO 
79 GANDHI 47 M YES YES LT NO NO 
80 VASANTHA 50 F YES NO HT NO NO 
81 AMBIKA 40 F YES NO LT NO NO 
82 GOWSALYA 50 F YES YES LT NO NO 
83 MAHESWARI 43 F YES NO LT NO NO 
 
 
S.no Name Age Sex 
Rheumatoid  
arthritis 
Traditional  
risk factor 
Rheumatoid  
factor 
Ecg-ischemic 
Changes 
Echo 
abnormality 
84 SHEELA 30 F YES YES LT NO NO 
85 JOTHY 40 M YES YES HT YES YES 
86 KARUPPAIAH 48 M YES YES LT NO NO 
87 KANNIYAMMAL 52 F YES NO LT NO NO 
88 REGINAMARY 25 F YES NO HT NO NO 
89 SHANTHY 45 F YES YES LT NO NO 
90 MALARVIZHI 40 F YES NO LT NO NO 
91 LAKSMIGEVI 29 F YES NO HT NO NO 
92 MALARKODI 33 F YES NO LT NO NO 
93 MALA 30 F YES NO LT NO NO 
94 NARASHIMMAN 47 M YES YES HT YES YES 
95 KANCHANA 24 F YES NO LT NO NO 
96 ANJAMMAL 46 F YES NO LT NO NO 
97 MURUGAMMA 39 F YES NO LT NO NO 
98 KUMAR 27 M YES NO LT NO NO 
99 MARIMMAL 48 F YES NO LT NO NO 
100 MOHANAVALLI 43 F YES NO LT NO NO 
 
 
 
                     
 
 
ABBREVIATIONS 
ACL   : ANTI CARDIOLIPIN ANTIBODIES 
AMI   : ACUTE MYOCARDIAL INFARCTION 
APS   : ANTI PHOSPHOLIPID SYNDROME 
BMI   : BODY MASS INDEX 
CCP   : CITRULINATED CYCLIC POLYPEPTIDE 
CHD   : CORONARY HEART DISEASE 
CRP   : C-REACTIVE PROTEIN 
CVD   : CARDIO VASCULAR DISEASE 
ESR   : ERTHROCYTE SEDIMENTATION RATE 
HDL   : HIGH DENSITY LIPOPROTEIN 
IHD   : ISCHEMIC HEART DISEASE 
LDL   : LOW DENSITY LIPOPROTEIN 
RA   : RHEUMATOID ARTHRITIS 
RF   : RHEUMATOID FACTOR 
SLE   : SYSTEMIC LUPUS ERTHYMATOSUS 
TGL   : TRIGLYCERIDE 
VLDL  : VERY LOW DENSITY LIPOPROTEIN 
 
 
